Table 5.

Demographic characteristics and anatomical follow-up parameters of Group 3 (management with WJ-MSC + rEMS combination).

Patient no	Genetic mutation	Eye	Horizontal EZW		Vertical EZW		FAF field
			Time0	Time1	Time0	Time1	Time0	Time1
1	RHO	R	2.49	2.51	1.98	2.04	5.2	5.3
		L	2.61	2.63	2.20	2.24	5.7	5.8
2	USH2A	R	6.18	6.21	5.72	5.74	34.2	35,7
		L	6.14	6.16	5.68	5.71	34.9	36,2
3	RPGR	R	1.21	0.85	1.34	0.94	1.6	1.3
		L	1.31	0.92	1.39	0.97	1.8	1.3
4	C2ORF	R	4.72	4.68	4.61	4.57	21.6	20.5
		L	4.63	4.57	4.58	4.52	21.2	20.3
5	USH2A	R	4.02	4.02	4.06	4.05	14.9	14.8
		L	4.22	4.21	4.26	4.26	18.0	18.0
6	PDE6B	R	3.56	3.50	3.69	3.62	14.1	13.8
		L	3.63	3.55	3.74	3.68	14.6	14.2
7	RP1	R	2.05	1.97	2.03	1.96	4.7	4.5
		L	2.11	2.07	2.10	2.04	5.0	4.7
8	USH2A	R	3.14	3.14	3.18	3.18	10.0	10.0
		L	3.22	3.21	3.28	3.27	10.5	10.5
9	PDE6A	R	3.29	3.21	3.22	3.17	10.6	10.3
		L	3.17	3.10	3.28	3.21	10.4	10.1
10	USH2A	R	2.98	2.98	3.00	3.00	9.1	9.1
		L	3.11	3.11	3.08	3.08	9.6	9.6
11	BBS6	R	2.01	2.00	2.11	2.10	4.2	4.2
		L	2.10	2.08	2.06	2.05	4.4	4.3
12	RHO	R	3.56	3.58	3.54	2.56	13.0	13.1
		L	3.68	3.69	3.66	3.67	13.6	13.7
13	RHO	R	4.71	4.71	4.68	4.68	23.6	23.6
		L	4.89	4.90	4.59	4.59	24.1	24.1
14	USH2A	R	2.97	2.97	2.91	2.91	9.8	9.8
		L	2.91	2.90	2.83	2.83	9.2	9.2
15	EYS	R	1.56	1.52	1.59	1.55	2.5	2.3
		L	1.63	1.58	1.58	1.53	2.7	2.5
16	RHO	R	5.10	5.09	5.05	5.03	30.6	30.5
		L	5.21	5.19	5.11	5.09	31.9	31.7

Time0 (baseline): just before the WJ-MSC and Magnovision application.

Time1: 36th month after injection and 36th month of weekly rEMS sessions.

EZW, ellipsoid zone width (mm); FAF, fundus autofluorescence (mm²); rEMS, repetitive electromagnetic stimulation; WJ-MSCs, Wharton’s jelly derived mesenchymal stem cells.